David L. Vesely
-
- Heart Failure Treatment and Management 67
- Atrial Fibrillation Management and Outcomes 15
- Cardiovascular Function and Risk Factors 14
- Bioengineering top 2%
- Polymers and Plastics top 5%
- Oncology top 5%
- Peptidase Inhibition and Analysis 16
-
- Pigment Synthesis and Properties 19
-
- PI3K/AKT/mTOR signaling in cancer 18
- Receptor Mechanisms and Signaling 13
-
- Corrosion Behavior and Inhibition 17
David L. Vesely
296 papers receiving 5.7k citations
Peers
Comparison fields: 5 of 166
- Cardiology and Cardiovascular Medicine 2.1k
- Endocrinology, Diabetes and Metabolism 635
- Bioengineering 205
- Polymers and Plastics 507
- Oncology 834
Countries citing papers authored by David L. Vesely
This map shows the geographic impact of David L. Vesely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L. Vesely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L. Vesely more than expected).
Fields of papers citing papers by David L. Vesely
This network shows the impact of papers produced by David L. Vesely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L. Vesely. The network helps show where David L. Vesely may publish in the future.
Co-authorship network
The 25 scholars most cited alongside David L. Vesely, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Family of peptides synthesized in the human body have anticancer effects. | 2014 | 10 |
| 2 | 2010 | 3 | |
| 3 | 2007 | 6 | |
| 4 | 2007 | 14 | |
| 5 | 2005 | 42 | |
| 6 | 2004 | 33 | |
| 7 | 2004 | 36 | |
| 8 | 2002 | 3 | |
| 9 | 2001 | 11 | |
| 10 | 1996 | 7 | |
| 11 | 1996 | 5 | |
| 12 | 1994 | 11 | |
| 13 | 1994 | 35 | |
| 14 | 1994 | 10 | |
| 15 | 1990 | 37 | |
| 16 | 1989 | 29 | |
| 17 | 1989 | 64 | |
| 18 | 1989 | 21 | |
| 19 | 1987 | 110 | |
| 20 | Activation of guanylate cyclase by streptozotocin and 1-methyl-1-nitrosourea. | 1977 | 42 |
About David L. Vesely
David L. Vesely is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Nephrology, having authored 302 papers that have together received 5.9k indexed citations. Recurring topics across this work include Heart Failure Treatment and Management (67 papers), Pigment Synthesis and Properties (19 papers), PI3K/AKT/mTOR signaling in cancer (18 papers), Corrosion Behavior and Inhibition (17 papers), Peptidase Inhibition and Analysis (16 papers), Atrial Fibrillation Management and Outcomes (15 papers), Cardiovascular Function and Risk Factors (14 papers) and Receptor Mechanisms and Signaling (13 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (2.1k citations), Endocrinology, Diabetes and Metabolism (635 citations) and Bioengineering (205 citations). David L. Vesely has collaborated with scholars based in United States, Czechia and Russia. Frequent co-authors include A. Kalendová, William R. Gower, Chris J. Winters, Alan L. Sallman, Jaroslav Stejskal, Petr Kalenda, Gerald S. Levey, Douglas D. Schocken, David M. Rico and John R. Dietz.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.